LRRK2 and Parkinson disease: In a longitudinal study including non-manifesting LRRK2 G2019S carriers, the annual decline rate of 123I-FP-CIT binding did not show a significant difference between PD converters and non-converters32, suggesting that dopaminergic degeneration in LRRK2 carriers precedes the parkinsonian motor symptoms.